Dear Doctor, thank you for your interest in official IPT Certification and Training Seminars.
This training is open to all medical doctors and health practitioners who want to:
in the medical procedure “Insulin Potentiation Therapy®” (I.P.T.) and “Insulin Potentiation Therapy Low Dose®” (I.P.T.L.D.) Training and certification is given by the Senior I.P.T.®- I.P.T.L.D.® Instructor: Donato Pérez García, M.D.
At the end of your training you’ll be receiving an official I.P.T. Certification Letter and Official I.P.T. Physician Credential, with approved seal from the teaching institute, Hospital Angeles, signed by Donato Pérez García, M.D. Name and credentials will be uploaded in the Official List of Certified IPT Physicians, endorsed and approved by Donato Perez Garcia, in his web sites, blogs and social networks.
This training will include the following subjects:
What to be on the lookout before releasing the patient, and what do assisting nurses need to know and do about IPT.
* All documentation is private and confidential.
WELCOME DOCTOR!
CONTACT INFORMATION: drdonato3@iptldmd.com
The following is a rebuttal to self proclaimed "medical writters" about Insulin Potentiation Therapy IPT or IPTLD.
I will start by sharing a comment made by R.W. Moss about chemotherapy (extract reproduced from a public source at http://www.whale.to/c/moss.html): “RM: Chemotherapy is machismo practiced to the N'th degree. It is a war in which you are the battleground, lucky you, I mean you have to treat your body better than that. The folks that bring you the toxic chemicals that cause the cancer are then kind enough to bring you toxic chemicals that allegedly…..”
I have undertaken to write this rebuttal because insulin potentiation therapy (IPT/ IPTLD) has helped multitudes of people with cancer who had already undergone the conventional route of surgery, chemotherapy and radiation and whose oncology team explained that there was “nothing else we can do.” I have personally had hundreds of these types of patients come to our center and, guess what? There was and is something that can be done to be restored to health.
It is clear that the self called "medical writters" and editors R.Baratz, RW Moss, J Jones, have not studied the protocols or the science behind insulin potentiation therapy (IPT/IPTLD). Their position regarding IPT/IPTLD as reflected in their writtings posted on their Blogs has either evolved out of hearsay or their imagination, not honest research into the subject matter, which indicates that they are attempting to alter people’s opinion regarding this chemotherapy delivery system by ‘reference to “authority,” rather than by utilizing factual information in an effort to inform or educate. The following is a definition of this fallacious way of arguing utilized by Dr Baratz, MD, DDS, PhD:
“Argument from authority (also known as appeal to authority) is a fallacy of defective induction, where it is argued that a statement is correct because the statement is made by a person or source that is commonly regarded as authoritative. The most general structure of this argument is:
* Source A says that p is true.
* Source A is authoritative.
* Therefore, p is true.
This is a fallacy because the truth or falsity of a claim is not related to the authority of the claimant, and because the premises can be true, and the conclusion false (an authoritative claim can turn out to be false). It is also known as argumentum ad verecundiam (Latin: argument to respect),argumentum ad potentiam (Latin: argument to power), or ipse dixit (Latin: he himself said it).”
Even a cursory evaluation of the science underlying IPT/IPTLD reveals that all cancer cells studied have, not only many more insulin receptors on their surfaces, but that those receptors have up to a 60% greater affinity (stickiness) than usual insulin receptors on non-cancerous cells. Also, what becomes clear from an earnest evaluation of the research into this matter is that there is a 43% homology between insulin receptors and IGF-1 receptors. This aspect of receptor status regarding cancerous cells is an additionally, rather salient aspect of how it is that IPT/IPTLD works to target cancerous cells as well as increase the effectiveness of the chemotherapeutic agent(s) administered. Under these conditions, lower administered doses carry equal, if not more of a “punch.” IGF-1 receptors, once activated, initiates cells to begin dividing, which is a stage of the cell cycle wherein cells are more vulnerable, hence more easily and effectively eliminated. Although cancerous cells have an autocrine function (produce their own insulin and IGF=1), this is occurring at all times which stimulates and fuels their growth during all phases of the cell cycle. However, when this is purposely activated during treatment with a cytotoxic agent, there is greater destruction of the malignant cells being targeted.
Any physician who has worked in an emergency department knows that when a patient arrives in an unconscious condition, the standard protocol usually calls for a dose of naltrexone and a dose of glucose. The naltrexone to counteract opiate overdose and the glucose counteract insulin overdose. The protocol requires both of these agents since there is no information regarding how the person became unconscious. When glucose is administered intravenously (IV) to someone who is suffering from an insulin overdose, they quickly begin to regain consciousness and are often confused, wondering where they are and how they got there. In the vast majority of cases, the person who was “comatose” (unconscious) from insulin having produced a potentially lethal hypoglycemic state returns to normal with no long term, adverse effects. Although the duration that the person was “comatose” is never precisely known, clearly, it must have included, at least a few minutes prior to the ambulance’s arrival plus the duration of the ambulance ride to the ER.
With insulin potentiation therapy (IPT/IPTLD), no one is ever allowed to become, even slightly neurologically impaired and, of course never allowed to lose consciousness. IV glucose is administered immediately if even the slightest neurological impairment becomes evident, e.g., slurred speech and glucagon is available to be used if the glucose does not immediately reverse the condition. Although glucagon is always available, it has never been necessary to use it. Glucagon is a hormone like insulin, produced in the pancreas by the Islets of Langerhans cells. Insulin is produced by the beta cells while glucagon is produced by the alpha cells. They are the ‘yin and yang’ of blood glucose homeostasis. Glucagon has the opposite effect of insulin and therefore, is its natural ‘antidote.’ NO ONE HAS EVER DIED FROM INSULIN POTENTIATION THERAPY. The same cannot be said of conventionally delivered, high dose chemotherapy. As indicated previously, even a cursory evaluation of the protocols used in IPT/IPTLD make it clear that this concern discussed in Blogs like Quack Watch, Moss Reports regarding the potential neurological impairment resulting from acute hypoglycemia brought about by insulin from this therapeutic modality could never occur if one follows the established protocols.
Why have there been no clinical trials using insulin potentiation therapy? As is commonly known, most clinical trials are expensive and funded by pharmaceutical companies attempting to receive FDA approval for use of a drug or device. No pharmaceutical company has to date accepted the offer to fund a clinical trial utilizing IPT/IPTLD nor even attempted to develop a clinical trail in order to prove that one can use 90% less of a chemotherapeutic drug that has already received FDA approval for its use. The stockholders simply would not allow this. It would not be considered a fiscally sound use of corporate money. The only human trail was performed in Uruguay and funded by the government (reference included). The lead investigator, Dr Lasalvia, is a well respected member of the American Society of Clinical Oncology and the results of his small trail clearly demonstrated that insulin plus a lower dose of a chemotherapeutic agent was more effective than either the drug alone or insulin alone. Although there are similar trials being performed in other countries where funding can be obtained from sources other than pharmaceutical companies, none of the studies have been concluded at this time.
In conclusion, IPT/IPTLD has been used successfully since 1930. Since 1997 it was introduced to many countries for neurological infectious, other infectious diseases, i.e., Lymes, and cancer of almost every type, and all stages (I – IV). With this long history of successful use of a modality to deliver drugs in a targeted fashion, minimal side effects (toxicities) and with no deaths, it is truly a human tragedy that this modality has not been evaluated here in the United States beginning with animal models and progressing to humans, as do all of the drugs that receive FDA approval. To merely criticize and attempt to dissuade further evaluation of something with such great potential benefit to humans is not only a tragedy but should be an embarrassment to the scientific community at large.
How very easy it is to proclaim your self a “medical writer or critic” and think you can rule a lifetime legacy as “quackery”. These ignorant “critics” do a couple of Google searches, a few hour research on an 8-decade tradition and actually believe they are experts in the theme.
What a truly pathetic existence they must have.
The good name of my grandfather and my father have been under attack for decades now, attack on my protocol “Insulin Potentiation Therapy” and this will be tolerated no more.
Self proclaimed medical writers that abuse of their (?) prestige, come out!
They have been attacking my lifetime work and placing doubt over the effectiveness of IPT©- IPTLD® with no solid foundation, except non-medical opinions. But these are the “low blows” of a coward, who attacks behind comfortable desks and think they can undo a lifetime achievement from a laptop and steal a life saving treatment to cancer patients.
The testimony of IPT©- IPTLD® s effectiveness is living and breathing in every cancer patient that lives today in remission, beating in every healthy patient worldwide who overcame cancer when no other doctor gave them hope. IPT©- IPTLD® is hope and mere verbal attacks from you ignorant selfish people, who have no courage to tell it to my face, can undo. My office is open for discussion with you “Quackery Cowards” and dare to say these things to my face. I am not hiding like you are.
Unlike you people, I do have moral standards and courage to fight my opponents out in the open. I do not hide behind comfortable desks, I don’t offend or attack other professional’s based on Google searches and post whatever comes to mind. You are dealing with human lives, and they have the right to know TRUTH, and the TRUTH is that IPT©- IPTLD® is a successful alternative cancer treatment, proven for decades to save patients lives. The theoretical proof is here in my office, if you want it, come and get it! Stop tainting my family’s good name and stop poisoning peoples mind with LIES, take a stand and come out you Cowards! You’ve done enough damage. Think you know more about IPT? PROVE IT!
Yes IPT/IPTLD works, it is a treatment alternative for lasting and successful outcomes. Insulin Potentiation Therapy© or IPTLD®, it is a metabolic supported chemotherapy. It involves fasting, insulin and chemotherapy. This is not a miracle product or the cure that is hidden from you. It is a safe treatment alternative. Not all patients will benefit.
Here you find the name, geographic location & email of the health practitioners, qualified to perform IPT/IPTLD® ,trained by Donato Perez Garcia, MD,
Dr. Roberto Cesar Leite (Brasil)
CENTRO DE MEDICINA INTEGRADA
Rua Senador Xavier Da Silva 59
Bairro Sao Francisco
Curitiba, Parana. CEP: 80530-060
Telefone: 55.41.3018.2591
EMAIL: administrativo@robertocesarleite.com.br WhatsApp: 55.41.9961.0659
Dr. Thomas Lodi, MD, MD(H)
+66 (0)92 704 0361
Dr. Arman Lurye (Kazajistán)
Dr. Martin vonRosen (Germany)
Dr. Desanka Petricevic (Switzerland)
Dr. Olzhas Zhandossov (Kazajistan)
Dr. Lee Cheng Lok (Malaysia)
Dr. Sachihiko Okuno (Japan)
Dr. Helgard Dekant (Germany)
Dr. Catalin Cirstoveanu (Rumania)
Dr. Ivan Juras (Slovakia)
Dr. Margaret Jiin Ngu (Australia)
1896 October 22, Donato Perez Garcia 1 was born in Mexico City.
1920 Insulin discovered in Canada by Banting, Best, Mcleod & Collip.
1923 May 17, Donato 1 married Iréne Bellòn.
1924 Jul 21, Donato 1 received Medical Diploma.
1926 Donato 1 first injected himself with insulin.
1930 Jan 14, first patient with syphilis successfully treated using IPT.
1930 November 18, Donato Perez Garcia y Bellon 2 born.
1935 July 13, Dr. Perez Garcia 1 applied for US patent for use of IPT to treat syphilis.
1935 Dr. Perez Garcia 1(age 38) demonstrated IPT at Harvard in US.
1937/38 Dr. Perez Garcia 1 practiced IPT in San Antonio and Austin, Texas.
1938 Dr. Perez Garcia 1 invited by US Secretary of War Harry H. Woodring to demonstrate IPT at Saint Elizabeth's Hospital, Washington, D.C.
1938 Dr.Perez Garcia 1, publishes first article about IPT in Revista Medica Militar
1939 US patent 2,145,869 granted for IPT treatment of syphilis.
1939 Official documentrecognizing the effectiveness of IPT signed by Alberto P. Leon, Mexican Secretary of Health.
1940 Official documentrecognizing the effectiveness of IPT signed by J. Agustin Cástro, Mexican Secretary of Defense.
1941 Dr. Perez Garcia 1 set up clinic to successfully test IPT in Mexican military.
1943/44 Dr. Perez Garcia 1 invited to demonstrate IPT in US at Naval Hospital in San Diego.
1944 April 10, Time Magazine article about Dr. Perez Garcia 1 and IPT successes, the first international recognition of the work of a Mexican doctor.
1944 Mexican military loses national election in 1944, ending Dr. Perez Garcia 1 chance to be Mexican Secretary of Health.
1946 January, first patient of breast cancer successfully treated using IPT.
1948 Dr. Perez Garcia 1, cured ulcers with antibiotics and IPT, 49 years before treatment with antibiotics became standard practice in 1991.
1948 Nov. 12 Dr. Perez Garcia 1, presented ulcer results to 3rd. Cong. of Medicine in Mexico City.
1950 Dr.Perez Garcia 1, presented pyloric stenosis results to 9th. Cong. of Surgeons in Mexico City.
1953 Dr. Perez Garcia 1, published the first book about IPT, Terapia Celular (Cellular Therapy).
1955 Drs. Perez Garcia 1 and 2 reversed paralysis of polio in children with IPT.
1956 Dr. Perez Garcia y Bellon 2 joined Dr. Perez Garcia 1 medical practice.
1958 March 30, Dr. Perez Garcia 3 born in Mexico City.
1960s Dr. Perez Garcia y Bellon 2 developed and researched a simple medical diagnostic method, the Oncodiagnosticator.
1971 December 12, Dr. Perez Garcia 1 died of a stroke (age 75) at his Clinic in Mexico City.
1975 Steven G. Ayre,MD., met Dr. Perez Garcia y Bellon 2, studied with him and began to promote IPT research in the US.
1976 Jean-Claude Paquette,MD., met Dr.Perez Garcia y Bellon 2, and started practicing IPT in Quebec, Canada (and later in Haiti).
1982 Donato Perez Garcia 3joined Dr. Perez Garcia y Bellon 2 clinic, in the same office founded by Dr. Perez Garcia 1.
1986 Chris Duffield PhD, met Steven G. Ayre MD, starting a long involvement with IPT.
1986 Steven G. Ayre published a general article about IPT in Medical Hypotheses.
1987 Drs. Perez Garcia 2 and 3 successfully treated three patients with HIV/AIDS using IPT. 1988 May 21&22, Drs. Donato 2&3 ,a 2 day seminar on Donatian Therapy (Terapeutica Celular por el cambio de las constantes bio fisico quimico sanguineas) was given at Universidad de Guadalajara, Jalisco Mexico.
1988 November 11-12 &13, Drs. Donato 2&3 ,a Lecture on Donatian Therapy (Terapeutica Celular por el cambio de las constantes bio fisico quimico sanguineas) was given during the Second International Congress on Alternative Medicine organized by Universidad de Guadalajara, Jalisco, Mexico.
1988 November 3rd., Dr. Perez Garcia 3 moved from Mexico City to establish his practice in Tijuana, Baja California, near San Diego, California.
1989 January 30, Dr.Donato Pérez García y Bellón met with Anthony J Mastromarino, Ph.D., then Assistant Vice President for Research at The University of Texas MD Anderson Cancer Center and was invited to present IPT at the 42nd Conference.
1989 October 24-27, Dr. Ayre and Drs. Perez Garcia 2 & 3, a Poster presentation at the Forty-second Annual Conference on Fundamental Cancer Research, The University of Texas, M.D. Anderson Cancer Center entitled: Breast carcinoma treated by a regimen of low-dose chemotherapy and insulin: report of four cases and pharmacokinetic considerations.
1990 US patent 4,971,951 granted for IPT treatment of cancer and viral diseases.
1990 July, Dr.Donato Pérez García y Bellón visited Paris, France and meet Dr. C. Jacquillat at the Pitié-Salpètrière Medical Hospital and got invited to present IPT at the 3rd International Congress.
1990 December: Publication in the European Journal of Cancer (letter) entitled ‘’Neoadjuvant low-dose chemotherapy with insulin in breast carcinomas’’ (Eur J Cancer, 26, 1262-1263. 1990).
1991 February 6,7,8 & 9: Oral presentation at the Third International Congress on Neoadjuvant Chemotherapy, Paris, France. Title: ‘’Insulin plus low-dose CMF as neoadjuvant chemo-hormonal therapy for breast carcinomas". A write-up of this talk appeared in the July-August issue of Oncology: News (Vol. 17, No.4. 1991).
1991 December 2, IND submission to the FDA of a protocol entitled ‘’Neoadjuvant combination chemo-hormonal therapy for the treatment of breast carcinoma using CMF plus insulin’’. The intent of this protocol was to perform a small pilot study using IPT and low-dose chemotherapy in the treatment of subjects newly diagnosed with breast cancer (Stages I-IIIB). The Principal Investigator for this study was Ira J. Piel, M.D., F.A.C.P., a medical oncologist- hematologist affilliated with the Illinois Masonic Medical Center in Chicago, IL.
1992 May 1, Drs. Ayre and Perez García 2 & 3 submitted to the Cancer Therapy Evaluation Program (CTEP) of a "Best Case Series" of IPT treatment involving a variety of different cancers. The intent of this submission was to introduce the CTEP to the historical context of the practice of IPT abroad, and to demonstrate the kinds of clinical results that have been experienced with this practice over the last several decades.
1992 US patent 5,155,096 granted for IPT treatment of many diseases.
1993 May 27, Materials on IPT sent to the newly established Office of Alternative Medicine (OAM) at the National Institutes of Health. In subsequent communications with Dr. Michael Eskinazi at OAM, was given the opinion that IPT was more mainstream medicine than alternative therapy, and that it should be evaluated through established channels for evaluating such medical discoveries.
1993 July 22, telephone call from Dr. Michael Hawkins -formerly with CTEP and now with the Georgetown University Medical Center, Division of Medical Oncology –offering to perform an animal study to investigate the workings of IPT. Dr. Hawkins indicated that should the results of the animal studies be supportive of the IPT concept, there was the possibility that clinical trials of IPT in the management of Stage IV breast cancer might thereafter be undertaken at Georgetown University.
1993 August 25, Received a formal written proposal from Dr. Hawkins concerning the animal study, complete with itemized budget for same. Fund raising efforts for this study were begun through a not-for-profit corporation called Medical Renaissance Foundation. an entity that had been established expressly for the purpose of funding IPT-related research.
1993 December 26, Dr. Donato Pérez García y Bellón 2 visited Henry Cisneros at his home in San Antonio Texas.
1994 January 11, a call from Ms. Shirl Thomas at the Office of the Secretary of Housing and Urban Development, in Washington, D.C. The Secretary himself -the Honorable Henry G. Cisneros -was a personal friend of one of the Mexican physicians responsible for pioneering the practice of IPT - Donato Perez Garcia y Bellon, M.D. Following the Christmas holiday season during which the two had spent much time together in San Antonio, and during which time Dr. Perez Garcia had discussed IPT at some length with his friend, Mr.Cisneros had instructed Ms. Thomas to contact me on his behalf with the offer of whatever help he and his office might be able to give to help promote the scientific study and development of IPT in the United States.
1994 March 4, received a letter from Hassan S. Rifaat, M.D. President of Texas Health Innovators, a private not-for-profit corporation with the following mission statement: I) To expedite the objective scientific evaluation of health care innovations, 2) To promote the public and professional distribution of such scientific evaluations, 3) To promote and facilitate access to the health care innovations that work. 4) To achieve our goals in the most time and resource efficient way. Dr. Rifaat stated that IPT had been highly recommended to him by Michael J. Friedman, M.D., Associate Director of NCI's Cancer Therapy Evaluation Program - whose office had declined to formally study IPT back in September 1992. I informed Dr. Rifaat of the ongoing initiatives for the study of IPT with the animal study at Georgetown University Medical Center and developments in China. The possibility of funding for research was discussed.
1994 March 24, a presentation to the Cancer Treatment Research Foundation of the Cancer Treatment Centers of America requesting funding for the animal study at Georgetown University Medical Center .
1994 April, Collaborative efforts for the study of IPT undertaken with medical Personnel at the Xuzhou Medical College Cancer Center in Xuzhou, China.
1994 May 2, Acceptance of grant request to the Cancer Treatment Research Foundation to fund an animal study at Georgetown University Medical Center. This study was designed to investigate the effects of insulin on adriamycin cytotoxicity on human breast cancer cell explants in athymic nude mice.
1995 Jean-Claude Paquette MD printed his book about IPT, Médecine de l'Espoir (Medicine of Hope) and then died in a motor bike accident.
1996 First IPT website, one page, by Dr. Perez Garcia 3.
1996 September, Dr. Donato Pérez García y Bellon 2, visited Tony Mastromarino, Ph.D., Director of Scientific Research, Office of the Vice-President, M.D. Anderson Cancer Center in Houston, Texas. Dr. Mastromarino communicated his interest in IPT to Mary Ann Richardson, Ph.D., from the UT School of Public Health, who is co-PI of the OAM-funded Center for Alternative Research in Cancer there. Dr. Mastromarino had been responsible for the 1989 invitation to the Drs. Perez Garcia and Dr. Ayre to prepare their poster presentation for M.D. Anderson's Forty-second Annual Conference on Fundamental Cancer Research.
1996 November , Dr. Mary A Richardson conducts a site visit at the office of Dr. Perez Garcia in Tijuana, Mexico, and subsequently invites the Drs. Perez Garcia and Dr. Ayre to come to an OAM meeting to be held in Bethesda in August.
1997 August 4-6, NIH/OAM Conference on ‘’Monitoring and Evaluation Approaches for Integrated Complementary and Altemative Medicine Cancer Practices" held in Bethesda, MD. The purpose of the Conference was to launch an initiative to facilitate entry of extant cancer protocols into a Phase II clinical trials environment. The name of this initiative was ‘’Practice Outcomes Monitoring Evaluation System" (POMES). Dr. Ayre presented a paper entitled ‘’Best Case Series Approach: Insulin Potentiation of Chernotherapy’’ . Clinical cases were provided by the Drs. Donato Perez Garcia.
1997 August 16 -29, Dr. Ayre visited for 14 days Dr. Donato Pérez García 3, in Tijuana to get trained on current IPT method and Dr. Ayre received his IPT practitioner certificate.
1997 September, Protocol for a multicenter prospective clinical trial of IPT in the treatment of stage IV cancers of the breast, lung, and ovary submitted to, and approved by, the Institutional Review Board of the Great Lakes College of Clinical Medicine at their fall meeting -September 16- 20, 1997, in Pittsburgh, PA.
1998 July 31, IPTQ.com (now also IPTQ.org and IPTQ.net) launched on web.
1999 March, Drs.Pérez García 2 & 3, received an invitation from Jeffrey D. White, M.D., Director, Office of Cancer Complementary and Altemative Medicine to present a Best Case Series on the clinical experience with IPT before the members of the Cancer Advisory Panel of the Center for Cancer Complementary and Altemative Medicine at the National Institutes of Health.
1999 October 20, Jean-Claude Paquette's book Médecine de l'Espoir made public for the first time, on IPTQ, in original French.
1999 December 19, English translation (by Aimé Ricci) of Medicine of Hope, Jean-Claude Paquette's book, published on IPTQ.
2000 March, Dr. Ross Hauser received IPT training by Dr. Donato Pérez García 3 in Tijuana BC, Mexico.
2000 May 8, IPTQ.org submitted to all major search engines over the Internet.
2000 June, Drs. Frank George and Hayle Aldren received IPT training by Dr. Donato Pérez García at his Tijuana office.
2000 September 18, Dr. Donato Pérez García 3, presented their best cancer cases to NIH Cancer Advisory Panel for Complementary and Alternative Medicine (CAPCAM) in Bethesda MD.
2000 October, Dr. Robert Rowen received IPT training by Dr. Donato Pérez García 3 at his Tijuana office.
2000 November 23 (Thanksgiving Day) Donato Perez Garcia y Bellon 2 ,age 70, died of a heart attack at home in Mexico City (17:15 CPT) .
2001 February 21-22, Las Vegas, Nevada the first IPT training seminar was held, bringing a total of 20 doctors plus one veterinarian.
2001 June 24, seven more doctors and one nurse received IPT training at the IPT workshop in Oklahoma City. The total number of practicing IPT doctors is now 37.
2002 January, Dr. Doug Brodie from Reno, NV, received IPT training by Dr. Donato Pérez García at his Tijuana office.
2002 January, The first doctors from France, Dr. Jean Remy Lepan and Dr. Nelson Modesto from Brazil, received IPT training by Dr. Donato Pérez García 3 at his Tijuana office.
2002 March, Dr. Philippe-Gaston Besson from Switzerland received IPT training by Dr. Donato Pérez García 3 at his Tijuana office. IPT is available now from 44 doctors worldwide, in 8 countries: the US, Canada, Mexico, Argentina, Brazil, France, Switzerland and Ecuador. Also, one veterinarian in Arizona.
2002 April, 5-6, 3rd IPT training workshop held in Dallas Texas.
2002 June, Publication of the first book in English entitled “Treating Cancer with Insulin Potentiation Therapy” by Ross A Hauser,M.D. and Marion A Hauser, M.S.,R.D.
2002 October 19 & 20, First IPT workshop in Curitiba, Brasil, organized by Dr. Donato Pérez García (3) and the Academia Sul-Americana de Medicina Integrada.
2002 November 6 & 7, Fourth IPT workshop organizad by Dr.Donato Pérez García, Bio-pro,Inc and the International Oxidative Medicine Association in Phoenix, AZ.
2002 November 7th. Phoenix,AZ. The First International Conference on Insulin Potentiation Therapy (IPT) organized by Dr. Donato Pérez García and Bio-pro, Inc. Sponsored by ATRIUM Biotechnologies.
2003 January 27. The first doctor from Asia, Seoul, Korea, Dr.Byung Gwon Park is trained by Dr.Donato Pérez García. IPT is available now from 80 doctors worldwide, in 10 countries: the US, Brasil, Canada, Mexico, Argentina, France, Switzerland, Ecuador, Venezuela and Ecuador. Also one veterinarian in Arizona.
2003 April 2 & 3. Phoenix, AZ. GORDON RESEARCH INSTITUTE (GRI), the INTERNATIONAL OXIDATIVE MEDICINE ASSOCIATION (IOMA) and Bio-pro,Inc. are proud to sponsor the 5th advanced training workshop on Comprehensive Cancer Care utilizing Insulin Potentiation Therapy (IPT).
2003 August 4 & 5. Tijuana, BC.,Mex. Eight training workshop on Comprehensive Cancer Care utilizing Insulin Potentiation Therapy (IPT) organized by. Dr.Donato Pérez García.
2003 October 14 & 15. Tijuana, BC.,Mex. Ninith training workshop on Comprehensive Cancer Care utilizing Insulin Potentiation Therapy (IPT) organized by. Dr.Donato Pérez García.
2004 April 16 & 17. Munich, Gemany. Second European training workshop on Comprehensive Cancer Care utilizing Insulin Potentiation Therapy (IPT) organized by. Dr.Donato Pérez García and Dr.P.R.Desanka (Germany) with the participation of Dr. Thomas Kroiss (Austria).
2004 June 28-July 1, Playa del Carmen, QR., Mexico. Second International Conference on Insulin Potentiation Therapy (IPT) organized by Dr. Donato Pérez García. Scientific Coordinator: T.R.Shantha, MD (Stockbridge, GA)
2005 May 5 & 6.Miami, FL. USA. Third International Conference on Insulin Potentiation Therapy (IPT) organized by Dr. Donato Pérez García. Scientific Coordinator: Frank W. George II DO MD(H) (Scottsdale, AZ. USA).
2006 October 21.Atlanta,GA, USA. Fourth International Conference on Insulin Potentiation Therapy (IPT) organized by Dr. Donato Pérez García. Scientific Coordinator: Donato Perez Garcia,MD.
2006 November 16 – 17. Maracay,Venezuela. Second Workshop in Spanish on Insulin Potentiation Therapy (IPT) organized by Dr. Donato Pérez García.
2007 October 20 – 20, Tijuana,BC,Mexico. Fifth International Conference on Insulin Potentiation Therapy (IPT) organized by Dr. Donato Pérez García. Scientific Coordinator: Donato Perez Garcia,MD.
2008 September 26 – 26. San Diego, CA.USA. Sixth International Conference on Insulin Potentiation Therapy (IPT) organized by Dr. Donato Pérez García. Scientific Coordinator: Les Brietman,MD. (Oceanside,CA.USA).
2010 October. Munich, Germany. Seventh International Conference on Insulin Potentiation Therapy (IPT) organized by Dr. Donato Pérez García.
2011 October. Viena, Austria. Eight International Conference on Insulin Potentiation Therapy (IPT) organized by Dr. Donato Pérez García.
2012 October. Madrid, Spain. Ninth International Conference on Insulin Potentiation Therapy (IPT) organized by Dr. Donato Pérez García.
2013 October. Munich, Germany. Ninith International Conference on Insulin Potentiation Therapy (IPT) organized by Dr. Donato Pérez García.
2014 October. Turkey, Istanbul. Tenth International Conference on Insulin Potentiation Therapy (IPT) organized by Dr. Donato Pérez García.
2015 February. Mexico City, Mexico. Global Quality Foundation. Gold Elite Award. Man of Leadership 2015 Distinction given to Dr. Donato Pérez García.
2015 October. Venezia, Italy. Eleventh International Conference on Insulin Potentiation Therapy (IPT) organized by Dr. Donato Pérez García.
2016 Publication of IPT Book in Japan by Dr. Sachihiko Okuno (Osaka, Japan)
2016 October. Sofia, Bulgaria Twelfth International Conference on Insulin Potentiation Therapy (IPT) organized by Dr. Donato Pérez García.
2017 October. Munich, Germany. Thirteenth International Conference on Insulin Potentiation Therapy (IPT) organized by Dr. Donato Pérez García.
2018 October. Tijuana, Mexico. Fourteenth International Conference on Insulin Potentiation Therapy (IPT) organized by Dr. Donato Pérez García.
2019 October. Fulda, Germany. Fifthteent International Conference on Insulin Potentiation Therapy (IPT) organized by Dr. Donato Pérez García.
2023 February. Avandaro, Valle de Bravo, Mexico. Sixteenth International Conference on Insulin Potentiation Therapy (IPT) organized by Dr. Donato Pérez García.
Copyright © 2024 Doctor Donato Perez Garcia & IPTLD - Todos los derechos reservados.
Con tecnología de GoDaddy